Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Colchicine/ropivacaine - PK MED

Next Previous
Drug Profile

Colchicine/ropivacaine - PK MED

Alternative Names: PKM-01

Latest Information Update: 29 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PK MED
  • Class Anilides; Anti-ischaemics; Antigouts; Antineoplastics; Antirheumatics; Colchicum alkaloids; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Gout

Most Recent Events

  • 14 Jun 2025 Pharmacodynamic data from a preclinical trial in Arthritis presented at 26th Annual Congress of the European League Against Rheumatism (EULAR 2025)
  • 14 Nov 2024 Pharmacodynamics data from preclinical studies in Gout flares presented at the ACR Convergence 2024
  • 27 May 2024 Colchicine/ropivacaine - PK-MED is available for licensing as of 27 May 2024. https://www.pk-med.com/partnering (PK MED pipeline, May 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top